Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P04637 (
p53
)
77,613
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The p53 binding protein, termed
p53BP2
, was identified as a protein interacting with protein phosphatase 1 (PP1) in the yeast two hybrid system. The interaction was confirmed by co-immunoprecipitation of
p53BP2
with epitope-tagged PP1 in vitro. The
p53BP2
-PP1 complex was stable to NaCl at concentrations which dissociate the
p53
-
p53BP2
complex, and the binding of PP1 and
p53
to
p53BP2
was mutually exclusive. The region required for interaction with PP1 was shown to be contained within amino acids 297-431 of
p53BP2
, which includes two ankyrin repeats. The phosphorylase phosphatase activity of PP1 was inhibited by
p53BP2
at nanomolar concentrations. These results suggest that PP1 may be involved in dephosphorylation and regulation of
p53
through interaction with
p53BP2
.
...
PMID:Protein phosphatase 1 interacts with p53BP2, a protein which binds to the tumour suppressor p53. 854 41
Using the yeast two-hybrid system, we have isolated a cDNA (designated BBP, for
Bcl2-binding protein
) for a protein (
Bbp
) that interacts with Bcl2.
Bbp
is identical to 53BP2, a partial clone of which was previously isolated in a two-hybrid screen for proteins that interact with
p53
. In this study, we show that specific interactions of
Bbp/53BP2
with either Bcl2 or
p53
require its ankyrin repeats and SH3 domain. These interactions can be reproduced in vitro with bacterially expressed fusion proteins, and competition experiments indicate that Bcl2 prevents
p53
from binding to
Bbp/53BP2
.
BBP/53BP2
mRNA is abundant in most cell lines examined, but the protein cannot be stably expressed in a variety of cell types by transfection. In transiently transfected cells,
Bbp
partially colocalizes with Bcl2 in the cytoplasm and results in an increased number of cells at G2/M, possibly accounting for the inability to obtain stable transfectants expressing the protein. These results demonstrate that a single protein can interact with either Bcl2 or
p53
both in yeast cells and in vitro. The in vivo significance of these interactions and their potential consequences for cell cycle progression and cell death remain to be determined.
...
PMID:The p53-binding protein 53BP2 also interacts with Bc12 and impedes cell cycle progression at G2/M. 866 6
The
p53-binding protein 2
(53BP2) was identified as a binding protein to a
tumor suppressor p53
. We examined the genetic aberrations of 53BP2 gene in various human cancer cell lines. Although no gross genomic alteration or mutation of 53BP2 gene was observed, 53BP2 mRNA levels were highly variable. There was no association between the 53BP2 mRNA level and the
p53
status. When we examined sensitivities of these cell lines to DNA-damaging agents including UV irradiation, X-ray irradiation and cis-diamine-dichloroplatinum (CDDP), we found that higher 53BP2 mRNA expression was correlated with the sensitivity to these agents.
...
PMID:Aberrant overexpression of 53BP2 mRNA in lung cancer cell lines. 1063 18
APCL, a central nervous system-specific sequence homologue of the adenomatous polyposis coli tumor suppressor, can regulate the cytoplasmic level of beta-catenin as the adenomatous polyposis coli tumor suppressor does, but its overall biological function remains unclear. Using a yeast two-hybrid system, we attempted to isolate proteins that might associate with the unique COOH-terminus of APCL. Among 166 cDNA clones isolated from a human fetal-brain cDNA library as candidates for interaction with APCL, 32 encoded parts of
p53-binding protein 2
(53BP2), a molecule that interacts with
p53
and Bcl2. An in vitro binding assay indicated that the Src-homology-3 domain and the ankyrin-repeat domain of 53BP2 were both required for binding to the COOH-terminus of APCL. Confocal microscopy showed that APCL and 53BP2 proteins were localized together in the perinuclei of normal mammalian cells, but this was not the case in cells that expressed truncated APCL and 53BP2 proteins. These findings suggested that binding of the COOH-terminus of APCL to 53BP2 regulates the cytoplasmic location of 53BP2. Because 53BP2 also interacts with
p53
and Bcl2 and regulates
p53
function, our results suggest that APCL might be involved in the
p53
/Bcl2-linked pathway of cell-cycle progression and cell death.
...
PMID:APCL, a central nervous system-specific homologue of adenomatous polyposis coli tumor suppressor, binds to p53-binding protein 2 and translocates it to the perinucleus. 1064 60
p53
interacts with a number of cellular proteins to form complexes which are probably crucial for its normal physiological function involving cell cycle control, gene regulation, cell differentiation, apoptosis and tumor suppression. To identify these proteins, we used the yeast two-hybrid system and screened a HeLa cDNA library. Six positive colonies were isolated from 1.5x10(6) transformants. The cDNA sequence of each positive colony was determined. Two novel cDNA fragments (p53BP1 and
p53BP2
) were cloned. These two cDNA fragments code for the same protein composed of 158 amino acids, which shows high similarity to the ubiquitin-conjugating enzyme (UBC9) of H. sapiens as well as to E2s from other organisms, such as UBC (76 %) of C. elegans, HUS5(66 %) of S. pombe, UBC(66 %) of A. thaliana and UBC9(56 %) of S. cerevisiae. A cDNA fragment from p53BP1 was used to probe a Northern blot containing poly(A)(+) RNA from various human tissues and various cell lines. At high stringency this probe hybridized to a single mRNA of approximately 1.2 kb that was expressed in heart, brain, placenta, liver, skeletal muscle, kidney, pancreas, spleen, thymus, prostate, testis, ovary, small intestine, colon, peripheral blood leukocyte, human cervical carcinoma cell (HeLa), human mammary carcinoma cell (MCF-7), human lymphoma cell (Jurkatt) and human teratocarcinoma cell (PA-I). It is not expressed in brain, lung, human lung carcinoma cell, human heptocellular carcinoma cell (HepG2) and human glioma cell(U251MG).
...
PMID:A Novel cDNA Encoding Ubiquitin-conjugating Enzyme of Homo sapiens. 1217 72
It is well established that
p53
is a primary target for mutation in human cancer.
p53
carries out the important task of ensuring that damaged DNA is not passed on during cell division, a duty that it performs by either inhibiting the cell cycle or inducing apoptosis. However, it is unclear how this decision is made. The recent identification of the ASPP family of proteins, which act to direct the cell away from cell cycle arrest and towards death following
p53
upregulation, may explain how this dilemma is resolved. Furthermore, the observation that ASPP2 is in fact the full length form of the previously identified 53BP2/
Bbp
protein has clarified the ambiguous data that has been generated in relation to this molecule. The further characterisation of these proteins will enable us to gain further insights into the response of the cell to DNA damage and the progression of the cell towards malignancy.
...
PMID:The ASPP family: deciding between life and death after DNA damage. 1262 42
The core protein of Hepatitis C virus affects several biological functions of the host cells such as cellular growth and apoptosis. The core was shown to interact with 53BP2/
Bbp
/ASPP2, a p53-binding protein, in a yeast two-hybrid assay. The core competed with
p53
in binding to ASPP2 in vitro. In an apoptosis assay using human osteosarcoma Saos-2 cells or hepatocellular carcinoma HepG2 cells, ectopic expression of
p53
induced apoptosis and ASPP2 enhanced this
p53
-induced apoptosis. However, coexpression of the core with
p53
and ASPP2 increased the number of surviving cells. In a reporter assay, neither ASPP2 nor the core with ASPP2 affected the transcriptional activity of
p53
on the promoters of Bax and p21, major p53 target genes. These findings suggest that the core inhibits
p53
-mediated apoptosis by blocking the interaction between
p53
and ASPP2, without modulating the transcriptional activity of
p53
, which plays a role in oncogenesis of hepatocellular carcinoma.
...
PMID:Hepatitis C virus core protein interacts with p53-binding protein, 53BP2/Bbp/ASPP2, and inhibits p53-mediated apoptosis. 1498 81
The p53 binding protein 2 (53BP2) has been identified independently as the interacting protein to
p53
, Bcl-2, and p65 subunit of nuclear factor kappaB (NF-kappaB). It was demonstrated that over-expression of 53BP2 (renamed as 53BP2S) induces apoptotic cell death. In this study we explored the effect of NF-kappaB activation elicited by a physiological NF-kappaB inducer, interleukin-1beta (IL-1beta), and anti-apoptotic Bcl-2 family proteins on the 53BP2S-mediated apoptosis. We found that both NF-kappaB activation and Bcl-2 family proteins could prevent the 53BP2S-mediated depression of mitochondrial transmembrane potential, activation of caspase-9, cleavage of poly ADP ribose polymerase (PARP), and cell death. These observations suggested that 53BP2S/
Bbp
and its directly or indirectly interacting proteins might play crucial roles in the regulation of apoptosis and contribute to carcinogenesis. It is also suggested that 53BP2S/
Bbp
induces apoptosis through the mitochondrial death pathway presumably by counteracting the actions of anti-apoptotic Bcl-2 family proteins. The regulatory network of the 53BP2S-mediated apoptosis cascade including its interacting proteins is discussed.
...
PMID:Inhibition of the 53BP2S-mediated apoptosis by nuclear factor kappaB and Bcl-2 family proteins. 1609 44
The
tumor suppressor p53
is frequently mutated in human cancers. Upon activation it can induce cell cycle arrest or apoptosis. ASPP2 can specifically stimulate the apoptotic function of
p53
but not cell cycle arrest, but the mechanism of enhancing the activation of pro-apoptotic genes over cell cycle arrest genes remains unknown. In this study, we analyzed the binding of 53BP2 (
p53-binding protein 2
, the C-terminal domain of ASPP2) to
p53
core domain and various mutants using biophysical techniques. We found that several
p53
core domain mutations (R181E, G245S, R249S, R273H) have different effects on the binding of DNA response elements and 53BP2. Further, we investigated the existence of a ternary complex consisting of 53BP2,
p53
, and DNA response elements to gain insight into the specific pro-apoptotic activation of
p53
. We found that binding of 53BP2 and DNA to
p53
is mutually exclusive in the case of GADD45, p21, Bax, and PIG3. Both pro-apoptotic and non-apoptotic response elements were competed off
p53
by 53BP2 with no indication of a ternary complex.
...
PMID:Effects of oncogenic mutations and DNA response elements on the binding of p53 to p53-binding protein 2 (53BP2). 1688 12
It is well known that insulin receptor substrates (IRS) act as a mediator for signal transduction of insulin, insulin-like growth factors, and several cytokines. To identify proteins that interact with IRS and modulate IRS-mediated signals, we performed yeast two-hybrid screening with IRS-1 as bait. Out of 109 cDNA-positive clones identified from a human placental cDNA library, two clones encoded 53BP2,
p53-binding protein 2
(53BP2S), a short form splicing variant of the apoptosis-stimulating protein of
p53
that possesses Src homology region 3 domain, and ankyrin repeats domain, and had been reported to interact with
p53
, Bcl-2, and NF-kappaB. Interaction of 53BP2S with IRS-1 was confirmed by glutathione S-transferase pull-down and co-immunoprecipitation assays in COS-7 cells and 3T3-L1 adipocytes. The Src homology region 3 domain and ankyrin repeats domain of 53BP2S were responsible for its interaction with IRS-1, whereas the phosphotyrosine binding domain and a central domain (amino acid residues 750-861) of IRS-1 were required for its interaction with 53BP2S. In CHO-C400 cells, expression of 53BP2S reduced insulin-stimulated IRS-1 tyrosine phosphorylation with a concomitant enhancement of IRS-2 tyrosine phosphorylation. In addition, the amount of the phosphatidylinositol 3-kinase regulatory p85 subunit associated with tyrosine-phosphorylated proteins, and activation of Akt was enhanced by 53BP2S expression. Although 53BP2S also enhanced Akt activation in 3T3-L1 adipocytes, insulin-induced glucose transporter 4 translocation was markedly inhibited in accordance with reduction of insulin-induced AS160 phosphorylation. Together these data demonstrate that 53BP2S interacts and modulates the insulin signals mediated by IRSs.
...
PMID:53BP2S, interacting with insulin receptor substrates, modulates insulin signaling. 1796 23
1
2
Next >>